<https://rdf.molmedb.upol.cz/reference/ref4009> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM493023>,
		<https://rdf.molmedb.upol.cz/interaction/method33>;
	<http://purl.org/ontology/bibo/pmid> "25655721"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM493026>,
		<https://identifiers.org/molmedb/MM493024>;
	<http://purl.org/dc/terms/bibliographicCitation> "Fukunaga K, Sakai D, Watanabe K, Nakayama K, Kohara T, Tanaka H, Sunada S, Nabeno M, Okamoto M, Saito K, Eguchi J, Mori A, Tanaka S, Inazawa K, Horikawa T.: Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease. Bioorg Med Chem Lett, Volume 25 (5), 2015"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/doi> "10.1016/j.bmcl.2015.01.005"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM493025>,
		<https://identifiers.org/molmedb/MM493022>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21> .
<https://rdf.molmedb.upol.cz/interaction/int1029645> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4009> .
<https://rdf.molmedb.upol.cz/interaction/int1029646> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4009> .
<https://rdf.molmedb.upol.cz/interaction/int1029647> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4009> .
<https://rdf.molmedb.upol.cz/interaction/int1029648> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4009> .
<https://rdf.molmedb.upol.cz/interaction/int1029644> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4009> .
